

Table 5.6d
Immunosuppression Use for Maintenance by Regimen
Prior to Discharge, 1998 to 2007
Recipients with Kidney Transplants

	Transplant Year									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Functioning Graft at Discharge	12,002	12,280	13,106	13,815	14,323	14,692	15,540	16,012	16,673	16,252
With Immunosuppression Info	11,933	12,093	12,889	13,790	14,259	14,617	15,407	15,786	16,466	15,884
CyA	0.3%	0.2%	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%	0.1%	0.1%
Tac	0.2%	0.2%	0.6%	1.1%	2.0%	1.0%	1.3%	1.4%	1.9%	1.5%
--- + MMF/MPA	0.3%	0.1%	0.1%	0.1%	0.2%	0.4%	0.4%	0.5%	0.5%	0.5%
CyA + MMF/MPA	0.7%	0.6%	0.9%	0.9%	0.7%	1.6%	1.7%	1.3%	2.0%	1.9%
Tac + MMF/MPA	0.6%	0.8%	1.1%	1.7%	2.9%	6.6%	13.7%	19.8%	24.3%	27.6%
--- + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet	0.2%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%
Tac + OtherAntimet	0.1%	0.0%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%
--- + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%
--- + Siro/Evero	0.0%	0.0%	0.1%	0.3%	0.1%	0.2%	0.4%	0.2%	0.0%	0.1%
CyA + Siro/Evero	0.0%	0.0%	0.1%	0.1%	0.4%	0.9%	1.2%	1.2%	1.1%	0.9%
Tac + Siro/Evero	0.0%	0.0%	0.4%	1.2%	1.3%	1.7%	1.9%	1.1%	0.9%	0.6%
--- + MMF/MPA + Siro/Evero	0.0%	0.0%	0.1%	0.2%	0.2%	0.4%	0.6%	0.4%	0.5%	0.2%
CyA + MMF/MPA + Siro/Evero	0.0%	0.0%	0.1%	0.2%	0.2%	0.2%	0.0%	0.0%	0.0%	0.0%
Tac + MMF/MPA + Siro/Evero	0.0%	0.0%	0.1%	0.2%	0.3%	1.2%	0.7%	0.5%	0.4%	0.3%
--- + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + Steroids	2.1%	1.9%	1.2%	1.0%	0.8%	1.3%	1.7%	1.3%	0.5%	0.4%
CyA + Steroids	5.4%	5.0%	3.1%	1.7%	1.2%	1.4%	1.4%	0.4%	0.3%	0.3%
Tac + Steroids	2.9%	3.2%	3.5%	3.9%	3.3%	2.3%	2.5%	2.3%	1.7%	2.0%
--- + MMF/MPA + Steroids	2.6%	2.8%	1.6%	1.4%	1.2%	1.6%	1.6%	2.0%	2.6%	2.4%
CyA + MMF/MPA + Steroids	48.2%	46.7%	37.1%	27.6%	22.9%	18.3%	14.3%	9.9%	6.7%	5.6%
Tac + MMF/MPA + Steroids	20.2%	26.4%	31.4%	38.6%	46.1%	46.8%	46.6%	50.3%	49.1%	51.4%
--- + OtherAntimet + Steroids	0.3%	0.3%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Steroids	8.8%	5.7%	3.6%	2.2%	0.8%	0.4%	0.2%	0.1%	0.1%	0.1%
Tac + OtherAntimet + Steroids	1.9%	1.4%	1.1%	1.3%	1.1%	0.9%	0.5%	0.2%	0.3%	0.2%
--- + Siro/Evero + Steroids	0.1%	0.2%	0.5%	0.5%	0.4%	0.6%	0.4%	0.2%	0.2%	0.1%
CyA + Siro/Evero + Steroids	2.9%	1.9%	5.0%	3.6%	2.8%	2.2%	1.4%	1.2%	1.2%	0.9%
Tac + Siro/Evero + Steroids	0.0%	0.2%	4.4%	6.4%	4.8%	4.7%	3.5%	2.4%	2.8%	0.9%
Other Regimen	2.3%	2.2%	3.7%	5.5%	5.9%	4.9%	3.7%	3.0%	2.5%	2.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Percentages in each column sum to 100 percent.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.